Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stake Trimmed by Quadrant Capital Group LLC

Quadrant Capital Group LLC lessened its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 16.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,800 shares of the medical device company’s stock after selling 1,148 shares during the period. Quadrant Capital Group LLC’s holdings in Tandem Diabetes Care were worth $209,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Baillie Gifford & Co. raised its holdings in shares of Tandem Diabetes Care by 235.7% during the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after acquiring an additional 523,843 shares during the period. GW&K Investment Management LLC raised its stake in Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after purchasing an additional 323,674 shares during the period. Stephens Investment Management Group LLC lifted its holdings in shares of Tandem Diabetes Care by 22.1% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock valued at $56,040,000 after purchasing an additional 281,327 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Tandem Diabetes Care by 89.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 515,062 shares of the medical device company’s stock worth $18,553,000 after buying an additional 242,965 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Tandem Diabetes Care by 397.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company’s stock valued at $11,121,000 after buying an additional 240,966 shares in the last quarter.

Tandem Diabetes Care Trading Down 2.8 %

Tandem Diabetes Care stock opened at $16.37 on Wednesday. Tandem Diabetes Care, Inc. has a 52 week low of $15.75 and a 52 week high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The firm has a market capitalization of $1.09 billion, a PE ratio of -8.48 and a beta of 1.52. The business’s 50-day simple moving average is $25.16 and its 200-day simple moving average is $31.59.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

TNDM has been the subject of several research analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Wells Fargo & Company reissued an “equal weight” rating and issued a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Robert W. Baird lowered their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. Barclays cut their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Finally, Sanford C. Bernstein cut shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $35.00 to $25.00 in a report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.38.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.